The Latest Cardiac and Vascular News
GENT, Belgium–(BUSINESS WIRE)–FEops, a cloud-based digital health player in the structural heart space, is glad to announce the nomination of Euan Thomson as a board member to its Board of Directors. “We are delighted to welcome Euan to the FEops Board of Directors. His wealth of knowledge and extensive expertise […]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Evasc Neurovascular is proud to announce the third generation of its eCLIPs™ device, the eCLIPs Bifurcation Flow Diverter. The new device is classified as a flow diverter, with a leaf density of 35%, which is 60% higher than the existing eCLIPs devices. As a result, the new […]
MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical sites for the currently enrolling ELPIS II Trial, evaluating Lomecel-B injection into the myocardium of […]
MONMOUTH JUNCTION, N.J., Oct. 20, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb®1 blood purification, makes additional comments on the investigator-initiated REMOVE study following the formal presentation of trial results on Saturday, October 16th at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Barcelona, Spain. […]
BOSTON, Oct. 20, 2021 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding Stealth’s New Drug Application […]
– Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent – GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent – Global COVID-19 testing-related sales were $1.9 billion in the third quarter – Excluding COVID-19 testing-related sales, third-quarter sales […]
PITTSBURGH, Oct. 20, 2021 – By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating pulmonary hypertension, or PH, a rare and incurable lung disease. Published today in Science Advances, the study used […]
IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place […]
ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment […]
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible for leading all clinical development at CinCor. “Mason will be guiding the clinical development programs for CIN-107 for multiple potential indications, including hypertension,” […]
